ATE243499T1 - Pharmazeutische zusammensetzungen mit kontrollierter freisetzung zur oralen verabreichung enthaltend nifedipin als wirkstoff - Google Patents

Pharmazeutische zusammensetzungen mit kontrollierter freisetzung zur oralen verabreichung enthaltend nifedipin als wirkstoff

Info

Publication number
ATE243499T1
ATE243499T1 AT97116153T AT97116153T ATE243499T1 AT E243499 T1 ATE243499 T1 AT E243499T1 AT 97116153 T AT97116153 T AT 97116153T AT 97116153 T AT97116153 T AT 97116153T AT E243499 T1 ATE243499 T1 AT E243499T1
Authority
AT
Austria
Prior art keywords
controlled release
oral administration
pharmaceutical compositions
active ingredient
release pharmaceutical
Prior art date
Application number
AT97116153T
Other languages
English (en)
Inventor
Roberto Valducci
Original Assignee
Valpharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valpharma Sa filed Critical Valpharma Sa
Application granted granted Critical
Publication of ATE243499T1 publication Critical patent/ATE243499T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/2027Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/44221,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/284Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846Poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT97116153T 1996-09-27 1997-09-17 Pharmazeutische zusammensetzungen mit kontrollierter freisetzung zur oralen verabreichung enthaltend nifedipin als wirkstoff ATE243499T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT96MI001983A IT1284604B1 (it) 1996-09-27 1996-09-27 Composizioni farmaceutiche a rilascio controllato per somministrazione orale contenenti nifedipina come sostanza attiva

Publications (1)

Publication Number Publication Date
ATE243499T1 true ATE243499T1 (de) 2003-07-15

Family

ID=11374935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97116153T ATE243499T1 (de) 1996-09-27 1997-09-17 Pharmazeutische zusammensetzungen mit kontrollierter freisetzung zur oralen verabreichung enthaltend nifedipin als wirkstoff

Country Status (13)

Country Link
US (1) US5871775A (de)
EP (1) EP0838218B1 (de)
JP (1) JPH10152440A (de)
CN (1) CN1110304C (de)
AT (1) ATE243499T1 (de)
AU (1) AU719075B2 (de)
BR (1) BR9706214A (de)
CA (1) CA2216277C (de)
DE (1) DE69723024T2 (de)
ES (1) ES2202528T3 (de)
IT (1) IT1284604B1 (de)
NZ (1) NZ328783A (de)
ZA (1) ZA978099B (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
US20040219210A1 (en) * 2003-05-01 2004-11-04 Jian-Hwa Guo Controlled release solid dosage nifedipine formulations
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
US20070026073A1 (en) * 2005-07-28 2007-02-01 Doney John A Amorphous efavirenz and the production thereof
CN101299993A (zh) * 2005-11-04 2008-11-05 伊士曼化工公司 用于给药难溶的药学活性剂的羧烷基纤维素酯
US20080085315A1 (en) * 2006-10-10 2008-04-10 John Alfred Doney Amorphous ezetimibe and the production thereof
US20080152717A1 (en) * 2006-12-14 2008-06-26 Isp Investments, Inc. Amorphous valsartan and the production thereof
US8613946B2 (en) * 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
WO2008092046A2 (en) * 2007-01-26 2008-07-31 Isp Investments Inc. Amorphous oxcarbazepine and the production thereof
JP5508859B2 (ja) * 2007-01-26 2014-06-04 アイエスピー インヴェストメンツ インコーポレイテッド 噴霧乾燥製品を製造するための調剤処理方法
DE102007048705A1 (de) 2007-10-11 2009-04-16 Bayer Healthcare Ag Amorphe Formulierung
WO2014016842A1 (en) * 2012-07-23 2014-01-30 Symed Labs Limited Amorphous coprecipitates of rivaroxaban
US9700549B2 (en) 2013-10-03 2017-07-11 David Wise Compositions and methods for treating pelvic pain and other conditions
CN109730967B (zh) * 2019-02-19 2021-08-03 广东工业大学 一种硝苯地平固体分散体及其制备方法
CN115844845B (zh) * 2022-08-29 2025-03-14 迪沙药业集团有限公司 一种硝苯地平缓释制剂及制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3033919A1 (de) * 1980-09-09 1982-04-22 Bayer Ag, 5090 Leverkusen Feste arzneizubereitungen enthaltend nifedipin und verfahren zu ihrer herstellung
EP0078430B2 (de) * 1981-10-29 1993-02-10 Bayer Ag Verfahren zur Herstellung von festen, schnellfreisetzenden Arzneizubereitungen mit Dihydropyridinen
EP0143857B1 (de) * 1983-11-30 1988-04-06 Siegfried Aktiengesellschaft Coronartherapeutikum in Form von Weichgelatine-Kapseln
JPS6136213A (ja) * 1984-07-27 1986-02-20 Rooto Seiyaku Kk 口腔用組成物
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
IT1187751B (it) * 1985-10-15 1987-12-23 Eurand Spa Procedimento per la preparazione di formulazioni solidi di nifedipina ad elevata biodisponibilita' e ad effetto prolungato e formulazioni cosi' ottenute
DE3738236A1 (de) * 1987-11-11 1989-05-24 Euro Celtique Sa Beisskapsel
GB8903328D0 (en) * 1989-02-14 1989-04-05 Ethical Pharma Ltd Nifedipine-containing pharmaceutical compositions and process for the preparation thereof
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
GB9200607D0 (en) * 1992-01-13 1992-03-11 Ethical Pharma Ltd Pharmaceutical compositions containing nifedipine and process for the preparation thereof
CN1120435A (zh) * 1994-01-04 1996-04-17 贵州泰康中医保健技术有限公司 硝苯吡啶缓释胶囊
CN1129103A (zh) * 1995-02-14 1996-08-21 永信药品工业股份有限公司 硝苯吡啶剂型的开发
DE19515972A1 (de) * 1995-05-02 1996-11-07 Bayer Ag Arzneizubereitungen mit kontrollierter Freisetzung und Verfahren zu ihrer Herstellung
SI9500173B (sl) * 1995-05-19 2002-02-28 Lek, Trofazna farmacevtska oblika s konstantnim in kontroliranim sproščanjem amorfne učinkovine za enkrat dnevno aplikacijo

Also Published As

Publication number Publication date
CA2216277A1 (en) 1998-03-27
ZA978099B (en) 1998-03-27
EP0838218A1 (de) 1998-04-29
AU719075B2 (en) 2000-05-04
CN1183960A (zh) 1998-06-10
DE69723024T2 (de) 2004-04-29
ITMI961983A1 (it) 1998-03-27
NZ328783A (en) 1998-02-26
JPH10152440A (ja) 1998-06-09
BR9706214A (pt) 1999-05-04
EP0838218B1 (de) 2003-06-25
CN1110304C (zh) 2003-06-04
AU3756797A (en) 1998-04-02
US5871775A (en) 1999-02-16
IT1284604B1 (it) 1998-05-21
DE69723024D1 (de) 2003-07-31
CA2216277C (en) 2003-06-10
ES2202528T3 (es) 2004-04-01

Similar Documents

Publication Publication Date Title
ATE243499T1 (de) Pharmazeutische zusammensetzungen mit kontrollierter freisetzung zur oralen verabreichung enthaltend nifedipin als wirkstoff
DK0723435T3 (da) Oral doseringsform af metoprolol til administration én gang dagligt
DK0510404T3 (da) Gastroresistente farmaceutiske formuleringer til oral administration indeholdende galdesyresalte
EP1468679A3 (de) Tramadolhaltiges Arzneimittel mit gesteuerter Wirkstoffabgabe
DE69206345D1 (de) Arzneimittel zur intranasalen Verabreichung, die Ketorolac R enthalten.
NO975872D0 (no) Formuleringer for kontrollert frigjöring av lite opplöselige medikamenter
TW355683B (en) Composition containing micronized nebivolol
NO20022014L (no) En fast oral kontrollert frigjorende doseringsform inneholdende hydrokodon
IL157963A0 (en) Hsa-free formulations of interferon-beta
ATE108657T1 (de) Galanthemin enthaltende pharmazeutische formulierung zur behandlung des alkoholismus.
AU5087290A (en) Transmembrane formulations for drug administration
HUP0302319A3 (en) Pharmaceutical composition for oral administration of active ingredient
SE9301171D0 (sv) Pharmaceutical composition containing lipophilic drugs
AU1351788A (en) Slow-release pharmaceutical agent
DE69307977D1 (de) Stabilisierte Derivate von Vitamin D2 und D3 enthaltende pharmazeutische Zusammensetzungen
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
DE60020501D1 (de) Trimetazidinhaltige Matrixtablette zur verlängerten Wirkstofffreisetzung nach oraler Gabe
ATE252377T1 (de) Kontrolliert freisetzende pharmazeutische zusammensetzung mit tilidinmesylat als wirkstoff
HUP0100024A3 (en) Pharmaceutical compositions for treating alzheimer's disease containing carvedilol as active ingredient
SE8804628D0 (sv) New compounds
AU3318389A (en) Azelastine-containing medicaments with controlled release of the active substance
IL92187A0 (en) Anti-human immunodeficiency virus compositions comprising fluorine-containing pyridonecarboxylic acid derivatives
LV10267A (lv) Savienojums arstniecibas lidzeklis panemiens savienojuma iegusanai
KR890701087A (ko) 부스피론 및 그의 염의 경구 투여용 제제
DE69301742D1 (de) Darreichungsformen mit verlaengerter Wirkstoffreigabe

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties